How Much Risk Should Big Pharma Accept To Close Deals In China? (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
SAN FRANCISCO - Big pharma may need to take a leap of faith to close deals in China, accepting greater risk in areas such as regulatory compliance and quality control, according to panelists during the 29th annual J.P. Morgan Healthcare conference in San Francisco
You may also be interested in...
Japanese Earnings Roundup: Shionogi Rebounds From U.S. Acquisition Woes With C&O Pharmaceutical For China; Astellas Ponders Mirabegron's Reproductive Warning
TOKYO - Shionogi & Co. Ltd. will expand its operations in China with the acquisition of C&O Pharmaceutical Technology Ltd., following through on a promise from its midterm plan to push into Asia to mitigate the 2016 patent loss of blockbuster Crestor (rosuvastatin)
Japanese Earnings Roundup: Shionogi Rebounds From U.S. Acquisition Woes With C&O Pharmaceutical For China; Astellas Ponders Mirabegron's Reproductive Warning
TOKYO - Shionogi & Co. Ltd. will expand its operations in China with the acquisition of C&O Pharmaceutical Technology Ltd., following through on a promise from its midterm plan to push into Asia to mitigate the 2016 patent loss of blockbuster Crestor (rosuvastatin)
Japan Earnings Roundup: Shinogi & Co.'s China Deal And Astellas Pharma Inc.'s Label Woes
Shionogi rebounds from U.S. acquisition woes with C&O Pharmaceutical for China; Astellas ponders Mirabegron's reproductive warning.